FdaApplication
NDA 211109
Identifiers
- fda_app_no: NDA211109
Properties
| Property | Value |
|---|---|
| applicant_name | TETRAPHASE PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2018-08-27 |
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XERAVA | ERAVACYCLINE DIHYDROCHLORIDE | EQ 50MG BASE/VIAL | POWDER;INTRAVENOUS |
| XERAVA | ERAVACYCLINE DIHYDROCHLORIDE | EQ 100MG BASE/VIAL | POWDER;INTRAVENOUS |
2 products